# A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.

> **NCT07266324** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Bright Minds Biosciences Pty Ltd** · enrollment: 16 (estimated)

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** BMB-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07266324
- **Lead sponsor:** Bright Minds Biosciences Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2026-11
- **Final completion:** 2027-03
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07266324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07266324, "A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07266324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*